Please login to the form below

Not currently logged in
Email:
Password:

NASH

This page shows the latest NASH news and features for those working in and with pharma, biotech and healthcare.

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH. Will acquire the US pharma group’s antisense drug in a deal valued up to $330m. ... NASH is a hot topic in pharma development at the moment, with bigger companies inking licensing deals for new

Latest news

More from news
Approximately 7 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Taking a lean and careful approach Taking a lean and careful approach

    A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what else we can come up with there.”. ... The NASH market is expected to be worth $20bm by 2025 and financial brokers recently valued

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Oncology, immuno-oncology and central nervous system therapies once again topped the charts, but 2016 also saw the emergence of new areas, notably non-alcoholic steatohepatitis or NASH. ... With NASH appearing to be a long-term consequence of obesity it

  • Deal Watch December 2016 Deal Watch December 2016

    The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small molecules in the field of chronic inflammatory diseases, including psoriasis, rheumatoid arthritis, non-alcoholic steato-hepatitis (NASH),

  • Deal Watch September 2016 Deal Watch September 2016

    Taking advantage of the drop in Tobira's market cap following disappointing results from the phase IIb studies in NASH, Allergan still paid a significant amount to secure the business with ... This acquisition brings a phase I oral DPP 4, evogliptin, and

  • Deal Watch April 2016 Deal Watch April 2016

    Nimbus develops Acetyl-CoA Carboxylase (ACC) inhibitors for treatment of liver diseases with the lead compound, NDI-010976 in phase I for non-alcoholic steatohepatitis (NASH - a hot area this month

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Living with NASH: An Unexpected Diagnosis

    Living with NASH: An Unexpected Diagnosis. Published in eyeforpharma November 2017 by Mariel Metcalfe. ... With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH)

  • Research Partnership publishes 2017 Living with NASH report

    Living with Non-alcoholic Steatohepatitis (NASH) is a quantitative US study conducted online amongst patients. ... The report consists of 45-minute online interviews with 108 NASH or NAFLD patients; a small number of qualitative interviews were also

  • Research Partnership launches new patient Living With Non-alcoholic Steatohepatitis (NASH) report

    Living with Non-alcoholic Steatohepatitis (NASH) is a study conducted amongst 100 adults with NASH in the US. ... It will also uncover attitudes towards NASH compared to other co-morbid conditions such as diabetes and obesity.

  • Zinc Ahead Ltd

    Address:. The Zinc Building. 4240 Nash Court , Oxford Business Park South.

  • Research Partnership

    We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we provide custom solutions and strategic recommendations that go beyond research,

More from PMHub
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics